Clinical Trials Logo
  1. Home
  2. Carcinoma, Non-Small-Cell Lung
  3. NCT01088906

Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC — Phalcis  

Carcinoma, Non Small Cell Lung Clinical Trial

Official title:
Study of Pemetrexed Disodium Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous Cell Lung Cancer: a Phase IIA Pharmacogenomic Trial

Clinical Trial Summary

This is a study of pemetrexed disodium plus cisplatin as first-line therapy in patients with advanced non-squamous cell lung cancer. This is a phase IIA pharmacogenomic trial.

Clinical Trial Description

This is a non-randomized, phase IIA pharmacogenomic, open label, uncontrolled, efficacy study in patients with advanced non-squamous cell lung cancer as a first line therapy. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01088906
Study type Interventional
Source Spanish Lung Cancer Group
Contact
Status Terminated
Phase Phase 2
Start date January 2010
Completion date April 2014
View Details
See also
  Status Clinical Trial Phase
Completed NCT02135211 - Healthy Directions After Lung Surgery Pilot N/A
Completed NCT00191230 - Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer Phase 2
Withdrawn NCT01004419 - Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer Phase 1
Completed NCT01671332 - Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer Phase 2
Terminated NCT00905801 - Computed Tomography (CT) Perfusion Imaging of Lung Cancer N/A
Recruiting NCT00184964 - Validation of Coregistered CT-PET Imaging in Determining Tumor Volume and Atelectasis in Patients With Operable Non-Small-Cell Lung Cancer and Tumor Associated Atelectasis N/A
Completed NCT00191256 - Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer Phase 2
Completed NCT00954278 - Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer Phase 1
Terminated NCT01282151 - TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer Phase 3
Completed NCT00553254 - Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer Phase 2
Completed NCT01469000 - A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC) Phase 2
Withdrawn NCT00934076 - Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer Phase 1
Completed NCT00798720 - Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer Phase 2
Terminated NCT01891669 - A Study Of PF-06263507 In Patients With Advanced Solid Tumors Phase 1
Completed NCT00160069 - Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer Phase 2
Completed NCT00548093 - PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib Phase 2